1. Low Frequency Ventilation During Cardiopulmonary Bypass to Protect Postoperative Lung Function in Cardiac Valvular Surgery: The PROTECTION Phase II Randomized Trial
- Author
-
Chris A. Rogers, Graziella Mazza, Rachel Maishman, Russell Thirard, Jonathan Evans, Samantha de Jesus, Chloe Beard, Gianni Angelini, Ann Millar, Nabil Jarad, Sally Tomkins, James Hillier, M‐Saadeh Suleiman, and Raimondo Ascione
- Subjects
cardiopulmonary bypass ,low frequency ventilation ,lung protection ,pulmonary function tests ,sRAGE ,valvular surgery ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Background Cardiac surgery with cardiopulmonary bypass (CPB) triggers pulmonary injury. In this trial we assessed the feasibility, safety, and efficacy of low frequency ventilation (LFV) during CPB in patients undergoing valvular surgery. Methods and Results Patients with severe mitral or aortic valve disease were randomized to either LFV or usual care. Primary outcomes included release of generic inflammatory and vascular biomarkers and the lung‐specific biomarker sRAGE (soluble receptor for advance glycation end products) up to 24 hours postsurgery. Secondary outcomes included pulmonary function tests and 6‐minute walking test up to 8 weeks postdischarge. Sixty‐three patients were randomized (33 LFV versus 30 usual care). Mean age was 66.8 years and 30% were female. LFV was associated with changes of sRAGE (soluble receptor for advance glycation end products) levels (geometric mean ratio, 3.05; [95% CI, 1.13–8.24] 10 minutes post CPB, and 1.07 [95% CI, 0.64–1.79], 0.84 [95% CI, 0.55–1.27], 0.67 [95% CI, 0.42–1.07], and 0.62 [95% CI, 0.45–0.85] at 2, 6, 12, and 24 hours post CPB respectively). No changes were observed for any of the generic biomarkers. Respiratory index soon after surgery (mean difference, −0.61 [95% CI, −1.24 to 0.015] 10 minutes post end of CPB), forced expiratory volume after 1 second/forced vital capacity ratio (0.050 [95% CI, 0.007–0.093] at 6 to 8 weeks pos‐surgery), Forced vital capacity alone (95% CI, −0.191 L [−0.394 to 0.012]) and 6‐minute walking test score at discharge (63.2 m [95% CI, 12.9–113.6]) were better preserved in the LFV group. No other differences were noted. Conclusions The use of LFV during CPB in patients undergoing valvular surgery was feasible and safe and was associated with changes in sRAGE levels along with better preserved lung function and walking performance. These observations warrant further investigation in larger future studies. Registration URL: https://www.isrctn.com; Unique Identifier: ISRCTN75795633.
- Published
- 2024
- Full Text
- View/download PDF